Clinical Pharmacogenetics Implementation Consortium ( CPIC ) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR 1 or CACNA 1S Genotypes
The identification in a patient of 1 of the 50 variants in the RYR 1 or CACNA 1S genes reviewed here should lead to a presumption of malignant hyperthermia susceptibility (MHS). MHS can lead to life‐threatening reactions to potent volatile anesthetic agents or succinylcholine. We summarize evidence...
Gespeichert in:
| Veröffentlicht in: | Clinical pharmacology and therapeutics 2019-06, Vol.105 (6), p.1338-1344 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1344 |
|---|---|
| container_issue | 6 |
| container_start_page | 1338 |
| container_title | Clinical pharmacology and therapeutics |
| container_volume | 105 |
| creator | Gonsalves, Stephen G. Dirksen, Robert T. Sangkuhl, Katrin Pulk, Rebecca Alvarellos, Maria Vo, Teresa Hikino, Keiko Roden, Dan Klein, Teri E. Poler, S. Mark Patel, Sephalie Caudle, Kelly E. Gordon, Ronald Brandom, Barbara Biesecker, Leslie G. |
| description | The identification in a patient of 1 of the 50 variants in the
RYR
1
or
CACNA
1S
genes reviewed here should lead to a presumption of malignant hyperthermia susceptibility (MHS). MHS can lead to life‐threatening reactions to potent volatile anesthetic agents or succinylcholine. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of these agents in patients with these
RYR
1
or
CACNA
1S
variants (updates at
https://cpicpgx.org/guidelines
and
www.pharmgkb.org
). |
| doi_str_mv | 10.1002/cpt.1319 |
| format | Article |
| fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1002_cpt_1319</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1002_cpt_1319</sourcerecordid><originalsourceid>FETCH-LOGICAL-c729-b37e2a7a402a78ebb435992c896b6403db03ba59cb74894aae0f4feb953f66f83</originalsourceid><addsrcrecordid>eNotkN1KAzEQRoMoWKvgI8xlvdiabPYvl8uitVC0tFXwasmmszaym5RNCvbRfDtT9WaGYfjOB4eQW0anjNL4Xu39lHEmzsiIpTyOspSn52REKRWRiHl2Sa6c-wxnIopiRL6rThutZAfLnRx6qewHGvRaOZj3-w57NF56bQ1U1jg7eH3oYQLVcl7BHcwOeosBgNDaAfwO4dUh2BaW1ocgvNkuhDuE0qAL78CFMhR4B9JsYX1QSptjp3b2F6LNLyM0efzyJ87qfQUMArsqq-cS2BpmaKw_7tFdk4tWdg5v_veYbB4fNtVTtHiZzatyEak8FlHDc4xlLhMaZoFNk_BUiFgVImuyhPJtQ3kjU6GaPClEIiXSNmmxESlvs6wt-JhM_rBqsM4N2Nb7QfdyONaM1ifjdTBen4zzH21MdY4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Clinical Pharmacogenetics Implementation Consortium ( CPIC ) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR 1 or CACNA 1S Genotypes</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Gonsalves, Stephen G. ; Dirksen, Robert T. ; Sangkuhl, Katrin ; Pulk, Rebecca ; Alvarellos, Maria ; Vo, Teresa ; Hikino, Keiko ; Roden, Dan ; Klein, Teri E. ; Poler, S. Mark ; Patel, Sephalie ; Caudle, Kelly E. ; Gordon, Ronald ; Brandom, Barbara ; Biesecker, Leslie G.</creator><creatorcontrib>Gonsalves, Stephen G. ; Dirksen, Robert T. ; Sangkuhl, Katrin ; Pulk, Rebecca ; Alvarellos, Maria ; Vo, Teresa ; Hikino, Keiko ; Roden, Dan ; Klein, Teri E. ; Poler, S. Mark ; Patel, Sephalie ; Caudle, Kelly E. ; Gordon, Ronald ; Brandom, Barbara ; Biesecker, Leslie G.</creatorcontrib><description>The identification in a patient of 1 of the 50 variants in the
RYR
1
or
CACNA
1S
genes reviewed here should lead to a presumption of malignant hyperthermia susceptibility (MHS). MHS can lead to life‐threatening reactions to potent volatile anesthetic agents or succinylcholine. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of these agents in patients with these
RYR
1
or
CACNA
1S
variants (updates at
https://cpicpgx.org/guidelines
and
www.pharmgkb.org
).</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1002/cpt.1319</identifier><language>eng</language><ispartof>Clinical pharmacology and therapeutics, 2019-06, Vol.105 (6), p.1338-1344</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c729-b37e2a7a402a78ebb435992c896b6403db03ba59cb74894aae0f4feb953f66f83</citedby><cites>FETCH-LOGICAL-c729-b37e2a7a402a78ebb435992c896b6403db03ba59cb74894aae0f4feb953f66f83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Gonsalves, Stephen G.</creatorcontrib><creatorcontrib>Dirksen, Robert T.</creatorcontrib><creatorcontrib>Sangkuhl, Katrin</creatorcontrib><creatorcontrib>Pulk, Rebecca</creatorcontrib><creatorcontrib>Alvarellos, Maria</creatorcontrib><creatorcontrib>Vo, Teresa</creatorcontrib><creatorcontrib>Hikino, Keiko</creatorcontrib><creatorcontrib>Roden, Dan</creatorcontrib><creatorcontrib>Klein, Teri E.</creatorcontrib><creatorcontrib>Poler, S. Mark</creatorcontrib><creatorcontrib>Patel, Sephalie</creatorcontrib><creatorcontrib>Caudle, Kelly E.</creatorcontrib><creatorcontrib>Gordon, Ronald</creatorcontrib><creatorcontrib>Brandom, Barbara</creatorcontrib><creatorcontrib>Biesecker, Leslie G.</creatorcontrib><title>Clinical Pharmacogenetics Implementation Consortium ( CPIC ) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR 1 or CACNA 1S Genotypes</title><title>Clinical pharmacology and therapeutics</title><description>The identification in a patient of 1 of the 50 variants in the
RYR
1
or
CACNA
1S
genes reviewed here should lead to a presumption of malignant hyperthermia susceptibility (MHS). MHS can lead to life‐threatening reactions to potent volatile anesthetic agents or succinylcholine. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of these agents in patients with these
RYR
1
or
CACNA
1S
variants (updates at
https://cpicpgx.org/guidelines
and
www.pharmgkb.org
).</description><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNotkN1KAzEQRoMoWKvgI8xlvdiabPYvl8uitVC0tFXwasmmszaym5RNCvbRfDtT9WaGYfjOB4eQW0anjNL4Xu39lHEmzsiIpTyOspSn52REKRWRiHl2Sa6c-wxnIopiRL6rThutZAfLnRx6qewHGvRaOZj3-w57NF56bQ1U1jg7eH3oYQLVcl7BHcwOeosBgNDaAfwO4dUh2BaW1ocgvNkuhDuE0qAL78CFMhR4B9JsYX1QSptjp3b2F6LNLyM0efzyJ87qfQUMArsqq-cS2BpmaKw_7tFdk4tWdg5v_veYbB4fNtVTtHiZzatyEak8FlHDc4xlLhMaZoFNk_BUiFgVImuyhPJtQ3kjU6GaPClEIiXSNmmxESlvs6wt-JhM_rBqsM4N2Nb7QfdyONaM1ifjdTBen4zzH21MdY4</recordid><startdate>201906</startdate><enddate>201906</enddate><creator>Gonsalves, Stephen G.</creator><creator>Dirksen, Robert T.</creator><creator>Sangkuhl, Katrin</creator><creator>Pulk, Rebecca</creator><creator>Alvarellos, Maria</creator><creator>Vo, Teresa</creator><creator>Hikino, Keiko</creator><creator>Roden, Dan</creator><creator>Klein, Teri E.</creator><creator>Poler, S. Mark</creator><creator>Patel, Sephalie</creator><creator>Caudle, Kelly E.</creator><creator>Gordon, Ronald</creator><creator>Brandom, Barbara</creator><creator>Biesecker, Leslie G.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201906</creationdate><title>Clinical Pharmacogenetics Implementation Consortium ( CPIC ) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR 1 or CACNA 1S Genotypes</title><author>Gonsalves, Stephen G. ; Dirksen, Robert T. ; Sangkuhl, Katrin ; Pulk, Rebecca ; Alvarellos, Maria ; Vo, Teresa ; Hikino, Keiko ; Roden, Dan ; Klein, Teri E. ; Poler, S. Mark ; Patel, Sephalie ; Caudle, Kelly E. ; Gordon, Ronald ; Brandom, Barbara ; Biesecker, Leslie G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c729-b37e2a7a402a78ebb435992c896b6403db03ba59cb74894aae0f4feb953f66f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gonsalves, Stephen G.</creatorcontrib><creatorcontrib>Dirksen, Robert T.</creatorcontrib><creatorcontrib>Sangkuhl, Katrin</creatorcontrib><creatorcontrib>Pulk, Rebecca</creatorcontrib><creatorcontrib>Alvarellos, Maria</creatorcontrib><creatorcontrib>Vo, Teresa</creatorcontrib><creatorcontrib>Hikino, Keiko</creatorcontrib><creatorcontrib>Roden, Dan</creatorcontrib><creatorcontrib>Klein, Teri E.</creatorcontrib><creatorcontrib>Poler, S. Mark</creatorcontrib><creatorcontrib>Patel, Sephalie</creatorcontrib><creatorcontrib>Caudle, Kelly E.</creatorcontrib><creatorcontrib>Gordon, Ronald</creatorcontrib><creatorcontrib>Brandom, Barbara</creatorcontrib><creatorcontrib>Biesecker, Leslie G.</creatorcontrib><collection>CrossRef</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gonsalves, Stephen G.</au><au>Dirksen, Robert T.</au><au>Sangkuhl, Katrin</au><au>Pulk, Rebecca</au><au>Alvarellos, Maria</au><au>Vo, Teresa</au><au>Hikino, Keiko</au><au>Roden, Dan</au><au>Klein, Teri E.</au><au>Poler, S. Mark</au><au>Patel, Sephalie</au><au>Caudle, Kelly E.</au><au>Gordon, Ronald</au><au>Brandom, Barbara</au><au>Biesecker, Leslie G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Pharmacogenetics Implementation Consortium ( CPIC ) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR 1 or CACNA 1S Genotypes</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><date>2019-06</date><risdate>2019</risdate><volume>105</volume><issue>6</issue><spage>1338</spage><epage>1344</epage><pages>1338-1344</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><abstract>The identification in a patient of 1 of the 50 variants in the
RYR
1
or
CACNA
1S
genes reviewed here should lead to a presumption of malignant hyperthermia susceptibility (MHS). MHS can lead to life‐threatening reactions to potent volatile anesthetic agents or succinylcholine. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of these agents in patients with these
RYR
1
or
CACNA
1S
variants (updates at
https://cpicpgx.org/guidelines
and
www.pharmgkb.org
).</abstract><doi>10.1002/cpt.1319</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9236 |
| ispartof | Clinical pharmacology and therapeutics, 2019-06, Vol.105 (6), p.1338-1344 |
| issn | 0009-9236 1532-6535 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_cpt_1319 |
| source | Wiley Online Library Journals Frontfile Complete |
| title | Clinical Pharmacogenetics Implementation Consortium ( CPIC ) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR 1 or CACNA 1S Genotypes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T06%3A41%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Pharmacogenetics%20Implementation%20Consortium%20(%20CPIC%20)%20Guideline%20for%20the%20Use%20of%20Potent%20Volatile%20Anesthetic%20Agents%20and%20Succinylcholine%20in%20the%20Context%20of%20RYR%201%20or%20CACNA%201S%20Genotypes&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Gonsalves,%20Stephen%20G.&rft.date=2019-06&rft.volume=105&rft.issue=6&rft.spage=1338&rft.epage=1344&rft.pages=1338-1344&rft.issn=0009-9236&rft.eissn=1532-6535&rft_id=info:doi/10.1002/cpt.1319&rft_dat=%3Ccrossref%3E10_1002_cpt_1319%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |